Retinalamin lyophilisate d / prig. solution for injection 5mg, No. 10

• Compensated primary open-angle glaucoma;

• diabetic retinopathy;

• central retinal dystrophy, incl. inflammatory and traumatic genesis;

• myopic disease (as part of complex therapy);

• central and peripheral tapetoretinal abiotrophy;

• rhegmatogenous and traumatic retinal detachment (rehabilitation postoperative period as part of complex therapy).

Adults

In diabetic retinopathy, central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy - parabulbar or i / m, 5-10 mg once a day. The course of treatment is 5-10 days; if necessary, repeat after 3Ц6 months.

With compensated primary open-angle glaucoma - parabulbar or intramuscularly, 5 mg 1 time per day. In the rehabilitation postoperative period of rhegmatogenous and traumatic retinal detachment, parabulbar 5 mg 1 time per day. The course of treatment is 10 days. With myopic disease, parabulbar 5 mg 1 time per day. The course of treatment is 10 days.

With myopic disease - parabulbar 5 mg 1 time per day. The course of treatment is 10 days. Recommended in combination with angioprotective agents and B vitamins.

The drug is dissolved in 1Ц2 ml of water for injection, 0.9% sodium chloride solution or 0.5% procaine (novocaine) solution, directing the needle to the wall of the vial to avoid foaming.

Children 1-5 years old

With central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy - parabulbar or i / m 2.5 mg once a day.

Children 6-18 years old

With central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy - parabulbar or IM, 2.5Ц5 mg 1 time per day.

The drug is dissolved in 1Ц2 ml of 0.9% sodium chloride solution, directing the needle to the wall of the vial to avoid foaming. The course of treatment is 10 days; if necessary, repeat after 3Ц6 months.

Precautions for use. RetinalaminЃ should only be used as directed by a physician!

The vial with the dissolved drug must not be stored or used after storage.

It is not recommended to mix RetinalaminЃ solution with other solutions.

Lyophilisate for the preparation of a solution for intramuscular and parabulbar administration

1 fl.

active substance: retinalamin (complex of water-soluble polypeptide fractions of the retina of cattle eyes) 5 mg

excipient (stabilizer): glycine - 17 mg

• Individual hypersensitivity to drug components;

• age up to 18 years - with compensated primary open-angle glaucoma, diabetic retinopathy, myopic disease, rhematogenous and traumatic retinal detachment (due to the lack of data on efficacy and safety);

• age up to 1 year - with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy.

pharmachologic effect

The drug has a stimulating effect on the photoreceptors and cellular elements of the retina, improves the functional interaction of the pigment epithelium and the outer segments of photoreceptors, glial cells in dystrophic changes, accelerates the restoration of light sensitivity of the retina. It normalizes vascular permeability, reduces manifestations of local inflammatory reactions, stimulates reparative processes in diseases and injuries of the retina.

The mechanism of action of RetinalaminЃ is determined by its metabolic activity: the drug improves the metabolism of eye tissues and normalizes the functions of cell membranes, improves intracellular protein synthesis, regulates lipid peroxidation processes, and helps to optimize energy processes.

Pharmacokinetics

The composition of RetinalaminЃ, the active ingredient of which is a complex of polypeptide fractions, does not allow for the usual pharmacokinetic analysis of its components.

Application during pregnancy and lactation

The drug is contraindicated in pregnancy (no data on efficacy and safety).

If necessary, the appointment of the drug during lactation, breastfeeding should be discontinued.

Application in children

Contraindicated:

• under the age of 18 - with compensated primary open-angle glaucoma, diabetic retinopathy (due to the lack of data on efficacy and safety);

• at the age of 1 year - with central retinal dystrophy of inflammatory and traumatic genesis, central and peripheral tapetoretinal abiotrophy.

special instructions

RetinalaminЃ should only be used as directed by a physician.

When using a 0.5% solution of procaine (novocaine) as a solvent for RETINALAMINЃ, you should adhere to the information on contraindications, precautions and age restrictions set out in the instructions for use of procaine (novocaine).

The vial with the dissolved drug must not be stored or used after storage.

It is not recommended to mix RetinalaminЃ solution with other solutions.

There are no peculiarities of the drug's action when taken for the first time or when it is canceled.

If the injection is missed, it is not recommended to inject a double dose, but to carry out the next injection as usual on the scheduled day.

No special precautions are required when disposing of unused medicinal products.

Influence on the ability to drive vehicles and mechanisms

Care should be taken when driving vehicles, mechanisms, because in the case of parabulbar injections of the drug and concomitant examination of vision, temporary visual impairments are possible, affecting the performance of potentially hazardous activities that require special attention and quick reactions (driving, working with moving mechanisms).

Overdose

No cases of drug overdose have been reported.

Drug interactions

The drug interaction of the drug RetinalaminЃ is not described.